Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Rheumatology PC

Neither a doctor nor a teaching hospital

Research payments

$844,232

241 payments

Through program year 2025, Advanced Rheumatology PC is reported as receiving $844,232 in research payments, across 241 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $148,039 36
2024 Research $79,244 19
2023 Research $64,694 23
2022 Research $210,917 58
2021 Research $103,203 50
2020 Research $189,091 51
2019 Research $49,044 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $436,091 176 payments
  2. Eli Lilly and Company $296,512 48 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $58,866 10 payments
  4. Ucb SA $34,668 3 payments
  5. Amgen Inc. $10,467 3 payments
  6. Novartis Pharmaceuticals Corporation $7,628 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Active-Controlled, Parallel-Group, Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $106,169 12 payments
  2. Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) $74,995 21 payments
  3. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $65,289 6 payments
  4. A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 $58,866 10 payments
  5. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $56,667 5 payments
  6. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) $56,568 16 payments
  7. M15-572 $43,038 13 payments
  8. M16-011 $39,853 9 payments
  9. A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. $34,668 3 payments
  10. A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy $34,277 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record